PIK3CD and systemic lupus erythematosus: Due to the engagement of the p110δ subunit of the PI3Kδ in human Th17 cells for the production of IL-17, this PI3K subfamily can be viewed as a promising molecular target for future therapies, including SLE [18,19,20,21].